Pulse nav.journalClub Debates activos Tendencias Explorar Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

Política de privacidad

Inicio Explorar nav.journalClub Tendencias

⌘+K

February 13, 2021Open Access

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme; CLEAR ClinicalTrials.gov number, NCT02811861.).

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma | Synapse

Cite This Study

Motzer et al. (Sat,) studied this question.

synapsesocial.com/papers/69d7c01a3b601d7be3ae2ae9 https://doi.org/https://doi.org/10.1056/nejmoa2035716

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma2020 · 134 citations
2696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial2020 · 116 citations
3Multiple Testing in Group Sequential Trials Using Graphical Approaches2013 · 121 citations
4Karnofsky performance status revisited: reliability, validity, and guidelines.1984 · 1,508 citations
5Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma2002 · 1,505 citations